Scientific work

Uzm. Dr. Erdoğan Şeyran

17 publications. The source of the information is stated next to each publication.

Back to profile

  1. Serum Procalcitonin for the Diagnosis of Spontaneous Bacterial Peritonitis in Patients With Decompensated Cirrhosis: A Prospective Study

    Eurasian Journal of Medical Advances, 2026

    DOI 10.14744/ejma.267011 Open-access full textSource: OpenAlex

  2. Association between gastric epithelial dysplasia and clinicopathological characteristics and overall survival in patients with metastatic gastric adenocarcinoma

    Journal of Medicine and Palliative Care, 2026

    DOI 10.47582/jompac.2013606 Open-access full textSource: ORCID

  3. Development of a Clinicopathological Prognostic Model and Risk Classification to Predict Disease-Free Survival in Patients with Gastric Adenocarcinoma Following Neoadjuvant Chemotherapy and Curative Gastrectomy

    Current Oncology, 2026

    DOI 10.3390/curroncol33090500 PMID 42782847 Open-access full textSource: ORCID

  4. Association of ABO and Rh blood groups with survival and clinicopathological characteristics in patients with gastric adenocarcinoma: a single-center retrospective study

    Journal of Current Hematology & Oncology Research, 2026

    DOI 10.51271/jchor-0090 Open-access full textSource: ORCID

  5. Integrating molecular and clinical determinants of survival in a real-world glioblastoma cohort

    Journal of Medicine and Palliative Care, 2026

    DOI 10.47582/jompac.1850445 Open-access full textSource: ORCID

  6. Beyond IMDC: do expanded models improve survival discrimination in metastatic renal cell carcinoma? A real-world cohort study

    Frontiers in Oncology, 2026

    DOI 10.3389/fonc.2026.1887870 PMID 42597456 Open-access full textSource: ORCID

  7. Pathological Complete Response and Residual Disease Patterns After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma: Clinical and Laboratory Associations

    Cancers, 2026

    DOI 10.3390/cancers18182983 PMID 42794949 Open-access full textSource: ORCID

  8. Prognostic Factors in Upper Gastrointestinal Neuroendocrine Carcinoma: A Retrospective Cohort Study of Clinicopathological Features and Survival Outcomes

    Cancer Management and Research, 2026

    DOI 10.2147/cmar.s618644 PMID 42483270 Open-access full textSource: ORCID

  9. Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer

    Journal of Oncology Pharmacy Practice, 2026

    DOI 10.1177/10781552231156521 PMID 36760158 11 citations (OpenAlex) Source: ORCID

  10. Association of Tumor Distribution Pattern with Stage at Diagnosis and Presentation Pattern in Patients with Invasive Breast Cancer

    Bagcilar Medical Bulletin, 2026

    DOI 10.4274/bmb.galenos.2026.16046 Open-access full textSource: OpenAlex

  11. Inflammatory and Nutritional Biomarkers for Overall Survival in Gastric Adenocarcinoma: Comparative Performance and Exploratory Temporal Patterns

    Diagnostics, 2026

    DOI 10.3390/diagnostics16213459 Open-access full textSource: OpenAlex

  12. Chat GPT Performance in Multi-Disciplinary Boards—Should AI Be a Member of Cancer Boards?

    Healthcare, 2025

    DOI 10.3390/healthcare13182254 PMID 41008386 12 citations (OpenAlex) Open-access full textSource: ORCID

  13. Clinicopathological Features and First-Line Treatment Outcomes of Geriatric Patients With Extensive-Stage Small Cell Lung Cancer: A Multicenter Study

    Cureus, 2023

    DOI 10.7759/cureus.35710 PMID 36875256 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  14. Adjuvant Capecitabine after Neoadjuvant Chemotherapy in Triple Negative Breast Cancer with Lymph Node Metastasis

    Journal of the College of Physicians and Surgeons Pakistan, 2023

    DOI 10.29271/jcpsp.2023.09.1012 PMID 37691363 1 citation (OpenAlex) Open-access full textSource: ORCID

  15. Vortex keratopathy associated with ribociclib

    Journal of Oncology Pharmacy Practice, 2023

    DOI 10.1177/10781552221101799 PMID 35570741 10 citations (OpenAlex) Source: ORCID

  16. Predictive and Prognostic Value of ABO Blood Group in Patients Using Immune Checkpoint Inhibitor for Advanced Renal Cell Carcinoma

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2022-90679 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  17. Predictive and prognostic effect of ABO blood group on immune checkpoint inhibitors

    Cancer Biomarkers, 2022

    DOI 10.3233/cbm-210455 PMID 35001878 3 citations (Europe PMC) Open-access full textSource: ORCID